Related Experiment Video
Updated: May 27, 2026
09:11
Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
Emerging drugs for diabetic retinopathy
Antonios Pipis1, Stefan Scholl, Albert J Augustin
1Staedtisches Klinikum Karlsruhe, Augenklinik, Karlsruhe, Germany.
Expert Opinion on Emerging Drugs
|November 25, 2011
Summary
New treatments for diabetic macular edema, including novel drugs and delivery systems, offer potential benefits for vision loss in diabetic retinopathy. Further trials are needed to confirm efficacy and safety.
Area of Science:
- Ophthalmology
- Diabetic Retinopathy Research
- Pharmacology
Background:
- Diabetic retinopathy is a leading cause of blindness, with diabetic macular edema being a primary driver of vision loss.
- Intravitreal treatments are emerging as key therapeutic options for ophthalmic complications of diabetes mellitus.
Purpose of the Study:
- To review current and emerging treatment options for diabetic macular edema.
- To discuss the scientific basis, benefits, and drawbacks of new therapeutic approaches for diabetic retinopathy.
Main Methods:
- Discussion of laser therapy for diabetic macular edema.
- Review of new pharmacological agents, including steroids and anti-vascular endothelial growth factor (anti-VEGF) compounds.
- Evaluation of novel biodegradable drug delivery systems.
Main Results:
- Anti-VEGF therapies show promise for proliferative diabetic retinopathy and macular edema.
- Biodegradable delivery systems enhance drug efficacy, safety, and cost-effectiveness.
- New treatments may offer sustained drug concentrations for longer periods.
Conclusions:
- Emerging treatments, particularly anti-VEGF compounds and advanced delivery systems, present a potential paradigm shift in managing diabetic macular edema.
- Further clinical trials are essential to validate the long-term efficacy and safety of these innovative therapies.
- Combination therapies may play a role in optimizing outcomes for diabetic retinopathy patients.
More Related Videos
10:07Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tg(fli:EGFP) Zebrafish Retinal Vasculature
Published on: December 26, 2017
08:10An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...